Rani Therapeutics Holdings Inc Cl A RANI

$0.53 +0.00 (0.21%)

Valuation

Market cap
73,364,000
Revenue TTM
$1,630,000
Net income TTM
$-29,670,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-1,820.25%
Debt to equity
0.00

Trading

Volume
552,800
Avg volume
530,688
Day's range
$0.50 – $0.54
Shares out
139,395,000
Stochastic %K
24%
Beta
0.61
Analysts
Strong Buy
Price target
$7.20

Price

Company profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including olig...

Show more

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Industry
Biotechnology
Sector
Healthcare
Phone
408 457 3700
Website
https://www.ranitherapeutics.com
Address
2051 Ringwood Avenue, San Jose, United States

Latest news

Stocktwits

Mjust Nov 15, 4:47 PM
$RANI As of Sept. 30, Rani reported $3.62M in cash and $41.67M in marketable securities, approximately $45.3M combined. The company also transferred to the Nasdaq Capital Market and has until May 10, 2027, to regain minimum bid-price compliance. The marketable securities provide additional liquidity, depending on their composition and maturity. However, the bigger questions are cash burn, funding requirements for clinical development, and potential dilution if additional capital is needed.
0 replies
Mandalo Nov 14, 11:11 AM
$RANI $RANI & Roche: The $1B+ Indirect Upside 🚀 Roche holds huge indirect potential for Rani Therapeutics via its majority stake in Chugai Pharmaceutical, Rani’s $1.085B licensing partner. Roche has the right of first refusal to sell Chugai’s drugs outside Japan. If their oral biologic succeeds, Roche’s global reach could unlock up to $100M in sales milestones and tiered royalties for $RANI. Plus, Chugai holds options on 5 extra targets, multiplying deal values. Success inside the Roche Group could spark direct Roche pipeline deals (non-dilutive cash) or make $RANI a prime long-term buyout target.
2 replies
Kingstockboy11 Nov 13, 9:23 PM
$RANI https://kalkinemedia.com/us/news/announcements/invus-group-and-raymond-debbane-reveal-999-stake-in-rani-therapeutics-class-a-shares
0 replies
Makingmillions192 Nov 13, 6:51 PM
$LEXX Top 5 Lexaria DehydraTECH (DHT) GLP-1 breakthroughs: 1. 55% Fewer GI Side Effects: Phase 1b human trials cut GI issues by 55% and overall adverse events by 48% vs. Rybelsus. 2. Oral Delivery of Injectables: Proven human oral absorption for injectable-only liraglutide and tirzepatide. 3. SNAC-Free Semaglutide: Delivers oral semaglutide without Novo Nordisk’s patented SNAC enhancer. 4. 566% Brain Penetration: Boosts GLP-1 brain tissue concentration in animal models to better target satiety. 5. Faster, Fed-State Absorption: Faster peak levels, steadier glucose, and works with food. Should be at $10 min right now.. $4.60 per share in cash on hand 70+ patented IP on technology 3 active MTAs with big pharma evaluating their technology This stock is a ticking time bomb 📈 🔥 $LLY $VKTX $RANI $PFE
0 replies
Mandalo Nov 13, 7:40 AM
$RANI On November 10, 2026, the Company received written notice from Nasdaq notifying the Company that it had approved the Company’s application to transfer the listing of its Class A common stock from The Nasdaq Global Market to The Nasdaq Capital Market and had granted the Company an additional 180 calendar days, or until May 10, 2027, to regain compliance with the Minimum Bid Price Requirement. The transfer to The Nasdaq Capital Market was effective at the opening of business on November 12, 2026. The Company’s Class A common stock will continue to trade under the symbol RANI https://ir.ranitherapeutics.com/sec-filings/sec-filing/8-k/0001193125-26-458489
2 replies
Jack696 Nov 12, 8:23 PM
$RANI effective today, this stock is garbage.
1 replies
KaShing01 Nov 11, 2:56 PM 1 replies
KaShing01 Nov 11, 2:55 PM
$RANI https://www.investing.com/news/earnings/rani-therapeutics-holdings-earnings-beat-by-001-revenue-topped-estimates-5013634
0 replies